

Marx, J. J. M.	341	Geisser, P., Rumyantsev, V.	373
Progress in intravenous iron treatment / Introduction		Pharmacodynamics and safety of ferric carboxy- maltose: a multiple-dose study in patients with iron-deficiency anaemia secondary to a gastro- intestinal disorder	
Funk, F., Ryle, P., Canclini, C., Neiser, S., Geisser, P.	345	Bailie, G. R.	386
The new generation of intravenous iron: chemistry, pharmacology, and toxicology of ferric carboxymaltose		Efficacy and safety of ferric carboxymaltose in correcting iron-deficiency anemia: a review of randomized controlled trials across different indications	
Malek, A.	354	Qunibi, W. Y.	399
<i>In vitro</i> studies of ferric carboxymaltose on pla- cental permeability using the dual perfusion model of human placenta		The efficacy and safety of current intravenous iron preparations for the management of iron- deficiency anaemia: a review	
Geisser, P., Banké-Bochita, J.	362		
Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose- escalation study in volunteers with mild iron- deficiency anaemia			

Key Word Index

Anaemia 341, 345, 354, 362, 373, 386, 399	Ferric carboxymaltose	Inflammatory bowel disease	373
Crohn's disease	Pharmacodynamics	Intravenous iron . 341, 345, 354, 362, 373,	
Ferinject® . . . 341, 345, 354, 362, 373, 386	Pharmacokinetics	386, 399	
Ferric carboxymaltose 341, 345, 354, 362,	Pharmacology	Iron deficiency . . 341, 345, 354, 362, 373,	
373, 386, 399	Placental permeability	386, 399	
Chemistry	Safety		
Efficacy	Toxicology		